教育干预对围手术期抗凝管理的影响
该研究采用回顾性队列与准实验设计,评估对初级保健医生和药师进行围手术期抗凝新证据教育后对临床决策的影响。结果显示,总体桥接率从38.8%降至24.8%(降幅14%,95%CI 2-26%,P=0.028),中危血栓栓塞组桥接率从63.8%降至30.2%(降幅33.6%,95%CI 14-53%,P=0.001);接受桥接的患者出血并发症更频繁,无血栓栓塞并发症。
要点
- 教育干预可显著降低中危血栓栓塞患者的桥接抗凝使用率。
- 接受桥接抗凝的患者出血并发症发生更频繁。
- 研究期间未观察到血栓栓塞并发症。
核心结论
- 向初级保健医生和药学人员提供围手术期抗凝新证据教育,可显著减少中危血栓栓塞风险患者使用桥接抗凝。
研究设计与样本
- 采用回顾性队列分析与准实验设计,纳入因机械心脏瓣膜、房颤或静脉血栓栓塞史而服用华法林并需中断治疗接受计划手术的成人患者,排除在明尼阿波利斯退伍军人事务抗凝门诊之外管理抗凝者。
主要发现
- 教育干预后总体桥接率从38.8%降至24.8%(降幅14%,95%CI 2-26%,P=0.028)。
- 中危血栓栓塞组桥接率从63.8%降至30.2%(降幅33.6%,95%CI 14-53%,P=0.001)。
- 接受桥接的患者出血并发症发生更频繁,未发生血栓栓塞并发症。
关键数值与推荐
- 总体桥接率下降14%(95%CI 2-26%,P=0.028)。
- 中危血栓栓塞组桥接率下降33.6%(95%CI 14-53%,P=0.001)。
临床怎么用
- 在围手术期抗凝管理中,可向初级保健医生和药学人员传播新证据以优化桥接抗凝决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The effect of education regarding new evidence in periprocedural anticoagulation, with a focus on reducing use in patients at only moderate thromboembolic risk, is presented. METHODS: A retrospective cohort analysis and quasiexperimental design were used. The initial review identified the current state of practice regarding bridging anticoagulation. Education was then provided to primary care providers and pharmacists on recent evidence. A subsequent review was completed to assess the impact of this education on clinical decision-making. Inclusion criteria were adults taking warfarin for an indication of mechanical heart valve, atrial fibrillation (AF), or history of venous thromboembolism (VTE) and required interruption of warfarin therapy to undergo a planned procedure. Patients were excluded if their anticoagulation was managed outside of the Minneapolis Veterans Affairs Anticoagulation Clinic. RESULTS: The overall rate of bridging decreased from 38.8% to 24.8% (14% decrease; 95% confidence interval [CI], 2-26%; p = 0.028) confidence interval [CI], 0.02-0.26; p = 0.026) after educational intervention. This decrease occurred in the moderate thromboembolic risk group, in which the bridging rate decreased from 63.8% to 30.2% (33.6% decrease; 95% CI, 14-53%; p = 0.001). Bleeding complications occurred more frequently in patients who received bridging. There were no thromboembolic complications. CONCLUSION: The majority of patients at moderate thromboembolic risk were previously receiving bridging until new evidence was released indicating that the risks may outweigh any benefits. The provision of education to primary care physicians and pharmacy staff regarding this new evidence in the area of periprocedural anticoagulation management significantly reduced the amount of bridging used for patients on warfarin for AF or a history of VTE who were at moderate thromboembolic risk.
引用
- Awker AL, Bell MA, McGraw M, et al. Impact of educational intervention on management of periprocedural anticoagulation. Am J Health Syst Pharm. 2017. PMID: 29167146. doi:10.2146/ajhp160726
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。